Journal profile · Pharmacology & Pharmacy
European Journal of Pharmaceutical Sciences
ISSN 0928-0987 · eISSN 1879-0720 · Elsevier · NETHERLANDS · Monthly · Founded 1993
European Journal of Pharmaceutical Sciences: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.01; fully open access; APC about USD 3,270; median 79 days to acceptance (107 articles, last 24 months); community-reported acceptance: easy (Elsevier website: 27%); 403 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
European Journal of Pharmaceutical Sciences is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Drug Transport and Resistance Mechanisms, together about 30.8% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
European Journal of Pharmaceutical Sciences is the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS).The journal publishes research articles, review articles, perspectives and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and drug development.More specifically, the European Journal of Pharmaceutical Sciences publishes reports on:drug absorption and metabolism,drug delivery including nucleic acid delivery,drug evaluation in the clinic,drug targeting,medicinal chemistry,personalised and precision medicine,pharmaceutical and biomedical analysis,pharmaceutical biotechnology,pharmaceutical technology and manufacturing,pharmacodynamics,pharmacokinetics,pharmacology including translational pharmacology,physical chemistry related to formulation, physical pharmacy and preformulation,regulatory science.New chemical entities, new biological entities, prodrugs, peptides and new modalities such as antibody-drug-conjugates (ADCs), PROTACs, advanced therapy medicinal products (ATMPs) including nucleic acid modalities (e.g., siRNA or mRNA), cell-based therapies are within the scope of the journal.Manuscripts describing new technical aspects such as new methods, new routes of synthesis, new formulation approaches, applied engineering, nanotechnology or the use of in silico tools for modelling and pharmaceutical data science are welcome.European Journal of Pharmaceutical Sciences publishes contributions dealing with relevant aspects of pediatrics, treatment of elderly patients e.g., impaired pharmacokinetics. Manuscripts covering rare diseases, are also within the scope of the journal.The journal will typically not give priority to manuscripts focusing exclusively on organic synthesis of bioactive small molecules and adaptation of analytical approaches, unless they prove to be of key importance in the drug discovery and development process. Topics or discussions pertaining to drug policy making do not have priority. In silico studies, such as molecular modelling, bulk scale modelling and virtual screening, unless reporting novel and broadly applicable methods, can be considered only if supported by experimental studies and verification of the pharmaceutical relevance of modelling results. Homeopathic medicines, phytochemical and pharmacological studies on plant extracts, traditional Chinese medicines and of isolated drug compounds of natural origin are not in the focus for European Journal of Pharmaceutical Sciences.Review articles, perspectives and scientific commentaries are generally by invitation or by consent of the Editors. Proceedings of scientific meetings may be published as special issues upon discussions with the Editor/Publisher.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Christoph SaalPublisher website
Editorial board by country: none in mainland China; most named United States 14, Denmark 6, Finland 6, Germany 5, Italy 4 (65 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics13.7%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics9.9%
- Drug Transport and Resistance MechanismsMedicine7.2%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.9%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics5.9%
- Human auditory perception and evaluationEngineering5.2%
- Analytical Chemistry and ChromatographyChemistry5%
- Nanoparticle-Based Drug DeliveryMaterials Science4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.01LetPub ·
- Impact factor (publisher)
- 5.1Publisher website ·
- CiteScore 2026-06
- 8.6LetPub ·
- CiteScore (publisher)
- 8.6Publisher website ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 1.22LetPub ·
- h-index
- 119LetPub ·
- h-index
- 186OpenAlex ·
- i10-index
- 5,208OpenAlex ·
- 2-year mean citedness
- 4.67OpenAlex ·
- Self-citation rate
- 5.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 362LetPub ·
Articles by year OpenAlex count · 9,738 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 236 | 236 | 115 |
| 2025 | 403 | 403 | 1,506 |
| 2024 | 293 | 293 | 2,735 |
| 2023 | 282 | 282 | 4,183 |
| 2022 | 233 | 233 | 4,404 |
| 2021 | 348 | 137 | 8,575 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 59 days – 129 days
- Acceptance to online
- median 1 days (107 articles)
- Submission to online
- median 81 days
- Sample
- 107 articles with submission and acceptance dates (727 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 27%LetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 39 daysPublisher website ·
- Submission to acceptance
- 95 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,270 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,070 / EUR 2,870 / GBP 2,460 / JPY 380,770 | — | — | |
| LetPub | USD 3,270 | Yes | — | |
| Publisher website | USD 3,270 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers4, by deadline
Publisher websiteWhat to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 1
- Reference style
- Author–date
- Templates
- LaTeX and Word
- Highlights
- Optional
Article types accepted9, with length limits
- commentariesCommentaries (Guidance) The definition of a Commentary for EJPS is three-fold. Firstly, it can be an argued piece of provocative scientific writing purporting t…Length not stated
- commentaryResearch articlesThe European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a f…Length not stated
- mini-reviewsCommentaries and Mini-reviews One page suggestions for comprehensive reviews, commentaries or mini-reviews should be sent to the Editor-in-Chief at christoph.sa…Length not stated
- research articleResearch articlesThe European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a f…Length not stated
- research articlesResearch articles The European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a …Length not stated
- reviewResearch articlesThe European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a f…main text ≤ 4,000 words
- review articleResearch articlesThe European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a f…Length not stated
- review articlesReview articles The manuscript of a review article should be arranged as described for research articles but according to the following sections: title page, ab…Length not stated
- viewpointResearch articlesThe European Journal of Pharmaceutical Sciences publishes research articles in the multidisciplinary field of pharmaceutical sciences, with a f…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
1 to 6 keywords required Model summary
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Monthly
- Founded
- 1993
- ISSN
- 0928-0987
- Electronic ISSN
- 1879-0720
- Society / sponsor
- European Federation for Pharmaceutical Sciences
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about European Journal of Pharmaceutical Sciences
What CAS zone is European Journal of Pharmaceutical Sciences in?
In the 2025 upgraded edition of the CAS Journal Ranking, European Journal of Pharmaceutical Sciences is in Zone 3 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of European Journal of Pharmaceutical Sciences?
The latest impact factor listed by LetPub is 5.01; CiteScore 8.6, h-index 186.
How long does peer review take at European Journal of Pharmaceutical Sciences?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 59–129 days); authors report an average review time of about 3 months; the community-reported acceptance is “Easy (Elsevier website: 27%)”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of European Journal of Pharmaceutical Sciences?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 1; Reference style: Author–date; Templates: LaTeX and Word; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of European Journal of Pharmaceutical Sciences based?
Of the 65 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (14), Denmark (6) and Finland (6). Counted from the institutions listed on the board page; for reference only.
Which databases index European Journal of Pharmaceutical Sciences?
According to LetPub and DOAJ records, European Journal of Pharmaceutical Sciences is indexed in SCIE, Scopus and DOAJ.
Is European Journal of Pharmaceutical Sciences open access, and what is the APC?
European Journal of Pharmaceutical Sciences is a fully open-access journal. APC about USD 3,270.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .